1068-90-2Relevant articles and documents
-
Snyder,Smith
, p. 350 (1944)
-
Improved Reagent for Electrophilic Amination of Stabilized Carbanions
Smulik, Jason A.,Vedejs, Edwin
, p. 4187 - 4190 (2003)
(Equation presented) Enolate amination using O-di(p-methoxyphenyl) phosphinylhydroxylamine 2 is reported. Reagent 2 reacts efficiently with stabilized sodium or potassium enolates derived from malonates, phenylacetates, and phenylacetonitriles and is sufficiently soluble for use in solution at -78°C.
Synthetic method of diethyl acetyl malonate
-
Paragraph 0020-0047, (2020/06/05)
The invention discloses a synthetic method for diethyl acetamidomalonate. The method comprises the following steps: firstly, performing a reaction in the presence of a metal salt and a ligand to prepare a mixed liquid containing the diethyl acetamidomalonate by taking diethyl malonate and acetamide as raw materials, air as an oxidant, and acetic acid as a solvent, performing distilling, and performing repeated extraction and recrystallization to obtain the diethyl acetamidomalonate in a white crystalline powder state. The method has the advantages that the metal salt and the ligand are cheap and easy to obtain, after the reaction is finished, the metal salt and the ligand can be further recycled through treatment, the air is taken as the oxidant, and therefore the production costs are greatly reduced; the yield of the product is more than 90%, the purity of the product is more than 99%, the conversion rates of the raw materials are high, and the reaction is complete; and the by-productis only water, no ''three waste'' (waste gas, waste water and solid waste) pollution problems exist, and the method meets environmental protection requirements.
NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES
-
Paragraph 0133; 0134; 0135; 0136; 0137, (2014/06/25)
The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.